Pentadeca Arginate (PDA): Evidence, Mechanism & Legal Status

Pentadeca Arginate ("PDA") is a clinic and marketing name for the arginine salt of BPC-157, promoted for tendon, ligament, gut and wound repair. It rose to prominence after late 2023 specifically as a compounding and marketing workaround, premised on the argument that a salt-form change makes it a "distinct" substance — an argument no FDA guidance has validated.11 This monograph separates the molecule from the marketing.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. PDA is not an FDA-approved drug; it is sold gray-market as a research chemical and is prohibited in sport. Dosing figures are reported strictly as seen in clinic and marketing materials for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is Pentadeca Arginate and how does it work?

"Pentadeca" denotes the fifteen amino acids; "arginate" denotes the arginine counter-ion of the salt. PDA is therefore BPC-157 by another name — the same sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, free-peptide molecular weight about 1419.5 g/mol, differing only in the salt paired with the peptide backbone.53 The arginate salt was defined in a 2013 Diagen patent family — WO2014142764A1, with US equivalent US 9,850,282 B2 issued December 26, 2017 — as "bepecin di-L-arginine salt," a pentadecapeptide salt carrying roughly two moles of basic amino acid per mole of peptide.4

The only pharmacologically meaningful difference versus the acetate salt is physicochemical, not receptor-level. Patent HPLC and accelerated-aging data argue the arginate form resists gastric-acid and thermal degradation far better than acetate — the patent reports acetate losing roughly 98 percent of structure within about five hours of simulated gastric acid versus about five percent for the arginate, supporting better oral stability and solubility.3 Vendor-cited figures of "about 1,000 times more stable at pH 3.0" and oral bioavailability rising "from under 3 percent to over 90 percent" trace to that patent or internal compounding documentation and have not been reproduced in any independent peer-reviewed study — treat them as unverified manufacturer claims.12 For the subcutaneous route most clinics actually market, the gastrointestinal-stability advantage is largely irrelevant because the peptide bypasses the stomach entirely.5

The mechanism is inherited from BPC-157 and entirely preclinical. Proposed actions — none established in humans — include upregulation of VEGF and VEGFR2-driven angiogenesis, nitric-oxide-system modulation, growth-hormone-receptor upregulation, collagen and tendon-fibroblast outgrowth, and gut-brain-axis modulation. No single primary receptor target has been confirmed.6 There are no published human pharmacokinetic data for PDA or BPC-157 — no Cmax, Tmax, validated half-life, or clearance; native-peptide plasma half-life is generally described as short (minutes), and systemic exposure after the marketed microgram subcutaneous doses is uncharacterized.1

What is the evidence by indication?

The overriding finding sets the ceiling for everything below: a 2025 PRISMA systematic review (Vasireddi et al., HSS Journal) screened 544 articles from 1993 to 2024 across PubMed, Cochrane and Embase; 36 met inclusion — 35 preclinical and only 1 human. Not one of those 544 papers studied "pentadeca arginate" as a distinct molecule.12 PDA-specific efficacy evidence is therefore absent, and the grades below reflect the borrowed BPC-157 base, with PDA-as-named graded D.

The orthopedic case is the most marketed. Rodent models report improved functional, structural and biomechanical healing of tendon, ligament, muscle and bone, plausibly via angiogenesis and fibroblast outgrowth — but there is no human randomized controlled trial.1 The single human datapoint across the entire field is an uncontrolled, unblinded retrospective case series of 12 patients with chronic knee pain given intra-articular BPC-157, in which 7 of 12 reported relief lasting more than six months — the lowest tier of evidence, with no control, no blinding and no validated outcomes.1 For the gut, BPC-157 was originally isolated from gastric juice and shows cytoprotective effects in animal models; secondary sources mention early Phase II work in ulcerative colitis, but no completed, peer-reviewed human results are available, and the arginate's claimed oral-stability edge is only the theoretical rationale for promoting PDA for gut indications.62

What doses appear in the literature?

Reported strictly as information, not a protocol — these figures come from clinic, marketing and compounding materials, not controlled trials, which do not exist.5 The most common route is subcutaneous injection of reconstituted lyophilized powder, often near the injury site; oral capsule and tablet forms are also marketed, leaning on the arginate salt's claimed acid stability.5 Reported dosing is roughly 250 to 500 micrograms subcutaneously once or twice daily for cycles of several weeks, mirroring conventional BPC-157 anecdotal dosing — there is no validated, trial-derived dose, titration or duration.5 Vendor reconstitution instructions describe bacteriostatic water and refrigeration; the patent notes sodium-bicarbonate co-formulation to further stabilize oral salt forms.3 Because PDA is sold gray-market as "research use only," product identity, purity, dose accuracy and sterility are unverified, and analyses of peptide-vendor products routinely find mislabeling and impurities.10

How safe is Pentadeca Arginate?

Reported adverse events are anecdotal and mostly mild: injection-site irritation, headache, nausea, dizziness, fatigue and transient blood-pressure fluctuations shortly after dosing.6 The animal toxicology record is reassuring at studied doses, but human safety data are too sparse to detect anything beyond the most obvious reactions.1 The central theoretical risk is angiogenesis and tumor support: because BPC-157 and PDA upregulate VEGF and VEGFR2 signaling, and those pathways drive the vascular supply of roughly half of human cancers, there is a biologically plausible, unresolved concern that the peptide could accelerate growth or metastasis of an existing tumor.6 Some 2025 work argues it regulates rather than indiscriminately drives angiogenesis and even shows anti-tumor signals in vitro, while critics counter that the "oncologic risk excluded" position does not cite solid-tumor in-vivo data.78 Active or recent malignancy and pregnancy or lactation are treated as contraindications; from a cautious, root-cause standpoint, the unsettled state of this debate is itself the safety signal.

What is the FDA and WADA status in 2026?

PDA is not FDA-approved, has no USP/NF monograph, and is not a component of any approved drug — so it meets none of the three statutory criteria for legal 503A bulk compounding.11 Critically, "pentadeca arginate" is not separately listed in any FDA bulks entry, guidance or ruling, and healthcare-law analyses conclude that a salt-form change does not create legal differentiation under the FDA's "essentially a copy" doctrine — the marketing premise that the arginate is a distinct, compounding-eligible substance is unvalidated.1112 On the timeline: the FDA added BPC-157 to the 503A Category 2 "significant safety risk" list in late 2023, then on April 15, 2026 removed it (and eleven other peptides) from Category 2 following nomination withdrawals — a move that did not confer approval or Category 1 status and left the substances in an unauthorized gray zone.13 A Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 is scheduled to evaluate BPC-157-related bulk substances, again with no separate "arginate" entry — underscoring that PDA tracks BPC-157's fate.1314

For athletes the picture is unambiguous. BPC-157 in any salt form, including PDA, has been prohibited at all times — in and out of competition — under WADA category S0 for non-approved substances since 2022, with no Therapeutic Use Exemption and validated detection methods; real sanctions have occurred.9 The salt form does not change the banned status, and the Department of Defense flags it for service members.10 Any WADA-tested athlete or service member should treat PDA as banned regardless of its shifting compounding status.

Bottom line. Pentadeca Arginate is a marketing rebrand, not a new drug — the arginine salt of BPC-157 that gained traction as a post-Category-2 compounding workaround premised on a salt-form "distinctness" no regulator has accepted. There are zero studies of PDA as a distinct molecule, and the borrowed BPC-157 base is 35:1 preclinical-to-human, with no RCTs. Graded D as "Pentadeca Arginate," C if generously crediting the parent preclinical base. Regulatory facts here are current as of June 2026; the July 23-24, 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date.